Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE NEVIRAPINE AND STAVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE NEVIRAPINE AND STAVUDINE.
EMTRIVA vs LAMIVUDINE, NEVIRAPINE, AND STAVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Lamivudine and stavudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by incorporating into viral DNA and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing a conformational change and inhibiting its activity.
Emtricitabine 200 mg orally once daily.
Lamivudine 150 mg, nevirapine 200 mg, and stavudine 30 mg (or 40 mg if weight ≥60 kg) orally twice daily for HIV treatment in adults.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Lamivudine: 5-7 hours (prolonged in renal impairment). Nevirapine: 25-30 hours (terminal, autoinduction reduces early half-life; significant accumulation). Stavudine: 1.0-1.6 hours (short; prolonged in renal impairment).
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Lamivudine: ~71% excreted unchanged in urine (glomerular filtration and active tubular secretion). Nevirapine: ~81% excreted in urine as glucuronide conjugates, <5% unchanged; ~10% in feces. Stavudine: ~40% excreted unchanged in urine (active tubular secretion), with remainder as metabolites.
Category C
Category A/B
Antiretroviral, NRTI
NRTI